Although several investigational drugs have shown significant preservation of C-peptide (a surrogate for endogenously produced insulin) in recent-onset T1D, direct effects on disease complications have never been shown as such events are rare in the first years after diagnosis in patients receiving standard of care treatment. Here, INS is linked to type 1 diabetes mellitus.